Evidence map›Paper›PMID 33751208›Full record

ArticleCancer immunology, immunotherapy : CII2021

Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.

Takeshi Ishikawa, Shinichi Kageyama, Yoshihiro Miyahara, Tetsuya Okayama, Satoshi Kokura, Linan Wang, Eiichi Sato, Hideo Yagita, Yoshito Itoh, Hiroshi Shiku

Open access · greenAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Application of nanomedicines in tumor immunotherapy.Journal of molecular cell biology · 2025
    Review
  10. Review
  11. Nanoimmunotherapy: the smart trooper for cancer therapy.Exploration of targeted anti-tumor therapy · 2025
    Review
  12. Review
  13. Review
  14. NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.Clinical and translational medicine · 2024
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Takeshi IshikawaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. iskw-t@koto.kpu-m.ac.jp.
Shinichi KageyamaDepartments of Immuno-Gene Therapy and Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan. kageyama@kaisehp.com.ORCID http://orcid.org/0000-0002-7682-3295
Yoshihiro MiyaharaDepartments of Immuno-Gene Therapy and Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan.
Tetsuya OkayamaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Satoshi KokuraDepartment of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Linan WangDepartments of Immuno-Gene Therapy and Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan.
Eiichi SatoDepartment of Pathology, Institute of Medical Science (Medical Research Center), Tokyo Medical University, Tokyo, Japan.
Hideo YagitaDepartment of Immunology, Juntendo University, Tokyo, Japan.
Yoshito ItohDepartment of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hiroshi ShikuDepartments of Immuno-Gene Therapy and Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan.
Kyoto Prefectural University of Medicine · JPMie University · JPJuntendo University · JPTokyo Medical University · JP

Funding

Japan Society for the Promotion of Science JP15K10093
6 · The paper itself

Abstract

The nanoparticle complex of cholesteryl pullulan (CHP) and NY-ESO-1 antigen protein (CHP-NY-ESO-1) presents multiple epitope peptides to MHC class I and II pathways, leading to CD8

Indexed as

Adjuvants, ImmunologicAgedAged, 80 and overAnimalsAntigens, NeoplasmCancer VaccinesCarboxymethylcellulose SodiumEsophageal NeoplasmsFemaleGlucansHumansInterferon InducersMaleMembrane ProteinsMiceMiddle AgedAdjuvants, ImmunologicAntigens, NeoplasmCancer VaccinesCarboxymethylcellulose SodiumCTAG1B protein, humanGlucansInterferon InducersMembrane ProteinsPoly I-Cpoly ICLCPolylysinepullulanCancer vaccineEsophageal cancerNY-ESO-1 antigenPoly-ICLC

Identifiers

PMID33751208
PMCPMC10991152
OpenAlexW3136839389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.